Cell No. : Cell Name TDC0001 : PDT-LUAD#5  update : 2025/04/23
Comment			Cancer organoid cell line.
Comment from the depositor			A patient derived lung cancer organoid harboring BRAF^(G469A).
Terms and conditions			1) The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior consent on use of it from the DEVELOPER and DEPOSITOR. The RECIPIENT shall conclude an MTA with the depositor. 2) In publishing research results obtained by the use of the BIOLOGICAL RESOURCE, a citation of the literature ref. (NPJ Precis Oncol. 2021 5(1):29) designated by the DEPOSITOR is required.
Remarks
Order Form			Order Form(C-0075.pdf)   Approval Form(C-0006.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)
			Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
	Basic information	IPR	Kawasaki Medical School
		Depositor	FUKAZAWA, Takuya
		Originator	FUKAZAWA, Takuya
		Year of deposit	2022
		Animal	_human < Mammals
		Genus	Homo
		Species	sapiens
		Race	Japanese
		Gender	Male
		Age at sampling	65
		Tissue	lung
		Disease name	left lung cancer
		Tumor	pulmonary adenocarcinoma, pT1cN2M0, pStage ⅢA
		Metastatic ability	Unknown
		Classification	cancer
		Recombinant	non-recombinant
		Year of origin	2018
		Lifespan	infinite
		Morphology	other
			deposit info	lot info
		Medium	Medium List
		Culture type	3D culture in matrigel	three-dimensional (3D) culture
		Culture medium	Sachs’s AO medium (Sachs, N. et al. EMBO J. 2019 38(4):e100300)	Sachs’s AO medium
		Antibiotics		Free
		Passage method		TrypLE Express
		Designated culture dish	24-well plate or 48-well plate	24-well plate
	Culture information	Passage ratio	1:4 to 1:8	1 : 3-4 split
		SC frequency	Subculture : once/week, Medium Renewal : 2 times/week	Subculture : once/7-10 days, Medium Renewal : 2 times/week
		Temperature	37 ℃	37 ℃
		CO2 concentration	5 %	5 %
		Freeze medium	CELLBANKER 1	CELLBANKER 1
		Freezing method		Slow freezing
		Mycoplasma/Acholeplasma		(-)
		Animal PCR		OK
		Others	Combination treatment of trametinib and erlotinib significantly suppressed the viability of this organoid.
		STR(human)		OK
Images			deposit info	lot info
Reference information		Reference	2
		User's Publication	0

Top

Reference

17019  Yokota E, Iwai M, Yukawa T, Yoshida M, Naomoto Y, Haisa M, Monobe Y, Takigawa N, Guo M, Maeda Y, Fukazawa T, Yamatsuji T.  Clinical application of a lung cancer organoid (tumoroid) culture system  NPJ Precis Oncol  2021  5(1):29  PubMed ID: 33846488   DOI: 10.1038/s41698-021-00166-3

17020  Sachs N, Papaspyropoulos A, Zomer-van Ommen DD, Heo I, Böttinger L, Klay D, Weeber F, Huelsz-Prince G, Iakobachvili N, Amatngalim GD, de Ligt J, van Hoeck A, Proost N, Viveen MC, Lyubimova A, Teeven L, Derakhshan S, Korving J, Begthel H, Dekkers JF, Kumawat K, Ramos E, van Oosterhout MF, Offerhaus GJ, Wiener DJ, Olimpio EP, Dijkstra KK, Smit EF, van der Linden M, Jaksani S, van de Ven M, Jonkers J, Rios AC, Voest EE, van Moorsel CH, van der Ent CK, Cuppen E, van Oudenaarden A, Coenjaerts FE, Meyaard L, Bont LJ, Peters PJ, Tans SJ, van Zon JS, Boj SF, Vries RG, Beekman JM, Clevers H.  Long-termLong-term expanding human airway organoids for disease modeling expanding human airway organoids for disease modeling  EMBO J  2019  38(4):e100300  PubMed ID: 30643021   DOI: 10.15252/embj.2018100300

Top

User's Publication